Recordati Industria Chimica e Farmaceutica SPA (0KBS) Price & Analysis

Compare

0 Followers

0KBS Stock Chart & Stats

€48.11

€0.25(0.48%)

At close: Jan 08 4:00 PM EST

€48.11

€0.25(0.48%)

Day’s Range― - ―

52-Week Range€44.04 - €55.30

Previous CloseN/A

Volume7.51K

Average Volume (3M)7.60K

Market Cap

€10.01B

Enterprise Value€11.81B

Total Cash (Recent Filing)€471.46M

Total Debt (Recent Filing)€2.54B

Price to Earnings (P/E)22.9

Beta0.91

Next Earnings

May 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.56

Shares Outstanding209,125,150

10 Day Avg. Volume8,262

30 Day Avg. Volume7,601

Financial Highlights & Ratios

PEG Ratio3.64

Price to Book (P/B)5.56

Price to Sales (P/S)4.46

P/FCF Ratio19.51

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€58.50

Price Target Upside21.60% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue GrowthConsistent revenue growth indicates a positive market position and effective product adoption, supporting long-term business expansion.

Balance Sheet HealthLow leverage enhances financial stability and flexibility, allowing for strategic investments and resilience against economic fluctuations.

Profitability MarginsStrong profitability margins reflect efficient operations and competitive pricing power, contributing to sustained financial performance.

Bears Say

Cash Flow ConcernsDeclining free cash flow growth could limit the company's ability to fund new projects and return capital to shareholders, impacting future growth.

EBIT And EBITDA MarginsDecreasing operational efficiency may signal rising costs or competitive pressures, potentially affecting profitability if not addressed.

EPS GrowthNegative EPS growth suggests challenges in maintaining earnings momentum, which could impact investor confidence and stock performance.

Recordati Industria Chimica e Farmaceutica SPA News

Recordati Industria upgraded to Equal Weight from Underweight at Barclays

Barclays upgraded Recordati Industria (RICFY) to Equal Weight from Underweight with an unchanged price target of EUR 48....

12d ago

Recordati Industria upgraded to Buy from Hold at Kepler Cheuvreux

Kepler Cheuvreux upgraded Recordati Industria (RICFY) to Buy from Hold with a price target of EUR 57.50, up...

20d ago

Recordati Updates Market on Progress of Share Buyback Programme

Recordati Industria Chimica e Farmaceutica SPA ( ($IT:REC) ) just unveiled an update. Recordati has provided an update...

13d ago

Recordati Reports January 2026 Treasury Share Purchases Under Ongoing Buy-back Program

Recordati Industria Chimica e Farmaceutica SPA ( ($IT:REC) ) just unveiled an announcement. Recordati disclosed that UBS Europe...

18d ago

Recordati Expands Treasury Stake with Continued Share Buyback for Incentive Plans

Recordati Industria Chimica e Farmaceutica SPA ( ($IT:REC) ) has issued an update. Recordati has provided an update...

20d ago

Recordati Strikes Global Deal With Moderna to Commercialize mRNA Therapy for Rare Metabolic Disease

The latest update is out from Recordati Industria Chimica e Farmaceutica SPA ( ($IT:REC) ). Recordati has entered...

25d ago

Recordati Sets 2026 Financial Calendar and Indicative Dividend Timetable

The latest update is out from Recordati Industria Chimica e Farmaceutica SPA ( ($IT:REC) ). Recordati S.p.A. has...

27d ago

Recordati price target lowered to EUR 48 from EUR 50 at Barclays

Barclays analyst Charles Pitman-King lowered the firm’s price target on Recordati (RCDTF) to EUR 48 from EUR 50...

2M ago

Recordati Updates Market on Progress of Share Buyback Programme

Recordati Industria Chimica e Farmaceutica SPA ( ($IT:REC) ) has provided an announcement. Recordati has provided an update...

2M ago

Recordati price target raised to EUR 70 from EUR 67 at JPMorgan

JPMorgan raised the firm’s price target on Recordati (RCDTF) to EUR 70 from EUR 67 and keeps an...

3M ago

Recordati Executes Treasury Share Sales Under Stock Option Plans

The latest announcement is out from Recordati Industria Chimica e Farmaceutica SPA ( ($IT:REC) ). Recordati has executed...

3M ago

Recordati Reports Strong Growth and Doubles Isturisa® Sales Estimates

Recordati Industria Chimica e Farmaceutica SPA ( ($IT:REC) ) has issued an announcement. Recordati reported strong financial results...

3M ago

Recordati Completes Share Buyback Program to Support Management Incentive Plans

An update from Recordati Industria Chimica e Farmaceutica SPA ( ($IT:REC) ) is now available. Recordati S.p.A. has...

4M ago

Recordati Appoints Mike McClellan as New CFO

Recordati Industria Chimica e Farmaceutica SPA ( ($IT:REC) ) has issued an announcement. Recordati has appointed Mike McClellan...

4M ago

0KBS FAQ

What was Recordati Industria Chimica e Farmaceutica SPA’s price range in the past 12 months?

Recordati Industria Chimica e Farmaceutica SPA lowest share price was €44.04 and its highest was €55.30 in the past 12 months.

What is Recordati Industria Chimica e Farmaceutica SPA’s market cap?

Recordati Industria Chimica e Farmaceutica SPA’s market cap is €10.01B.

When is Recordati Industria Chimica e Farmaceutica SPA’s upcoming earnings report date?

Recordati Industria Chimica e Farmaceutica SPA’s upcoming earnings report date is May 12, 2026 which is in 77 days.

How were Recordati Industria Chimica e Farmaceutica SPA’s earnings last quarter?

Recordati Industria Chimica e Farmaceutica SPA released its earnings results on Feb 17, 2026. The company reported €0.561 earnings per share for the quarter, missing the consensus estimate of €0.73 by -€0.169.

Is Recordati Industria Chimica e Farmaceutica SPA overvalued?

According to Wall Street analysts Recordati Industria Chimica e Farmaceutica SPA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Recordati Industria Chimica e Farmaceutica SPA pay dividends?

Recordati Industria Chimica e Farmaceutica SPA does not currently pay dividends.

What is Recordati Industria Chimica e Farmaceutica SPA’s EPS estimate?

Recordati Industria Chimica e Farmaceutica SPA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Recordati Industria Chimica e Farmaceutica SPA have?

Recordati Industria Chimica e Farmaceutica SPA has 209,125,150 shares outstanding.

What happened to Recordati Industria Chimica e Farmaceutica SPA’s price movement after its last earnings report?

Recordati Industria Chimica e Farmaceutica SPA reported an EPS of €0.561 in its last earnings report, missing expectations of €0.73. Following the earnings report the stock price went down -0.084%.

Which hedge fund is a major shareholder of Recordati Industria Chimica e Farmaceutica SPA?

Currently, no hedge funds are holding shares in GB:0KBS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Recordati Industria Chimica e Farmaceutica SPA

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat. It also provides products for rare diseases; and pharmaceutical chemicals, such as chemical syntheses, active pharmaceutical ingredients, and intermediates. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

Recordati Industria Chimica e Farmaceutica SPA (0KBS) Earnings & Revenues

Historic Earnings Reports

0KBS Stock 12 Month Forecast

Average Price Target

€58.50

▲(21.60% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"45":"€45","58":"€58","71":"€71","51.5":"€51.5","64.5":"€64.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":58.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€58.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€48.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[45,51.5,58,64.5,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.779,48.56523076923077,50.35146153846154,52.13769230769231,53.92392307692308,55.71015384615385,57.49638461538461,59.28261538461538,61.06884615384615,62.85507692307692,64.64130769230769,66.42753846153846,68.21376923076923,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.779,47.680615384615386,48.58223076923077,49.48384615384616,50.38546153846154,51.287076923076924,52.18869230769231,53.0903076923077,53.99192307692308,54.89353846153846,55.795153846153845,56.696769230769235,57.59838461538462,{"y":58.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.779,46.87292307692308,46.966846153846156,47.06076923076923,47.15469230769231,47.248615384615384,47.34253846153846,47.43646153846154,47.53038461538462,47.624307692307696,47.71823076923077,47.81215384615385,47.906076923076924,{"y":48,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":57.265,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":52.928,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":51.49,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":50.407,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":52.144,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.625,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.317,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.44,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.243,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.959,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.35,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.56,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.779,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >